Physician profile
Daniel W Lee
NPI 1336124056
$1,989.42
in general payments reported to CMS, 2019-2025
24 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $340 · 2021: $184 · 2022: $196 · 2023: $179 · 2024: $333 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $329.06 | 2019-2025 | Airsupra, Fasenra, Farxiga |
| Glaxosmithkline, LLC. | $282.65 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $165.04 | 2025 | Xembify |
| Microvention, INC. | $156.80 | 2022 | |
| Abbott Laboratories | $151.97 | 2019 | |
| Novo Nordisk INC | $133.60 | 2019-2021 | |
| Genzyme Corporation | $116.03 | 2023-2025 | |
| Lilly USA, LLC | $101.75 | 2020-2021 | |
| Pfizer INC. | $98.80 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.72 | 2024-2025 | Cuvitru |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.54 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $45.52 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $35.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.27 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $29.86 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $27.54 | 2025 | Neffy |
| Pharming Healthcare, INC. | $26.65 | 2023 | Ruconest |
| Bayer Healthcare Pharmaceuticals INC. | $24.67 | 2022 | |
| Biocryst US Sales Co., LLC | $22.50 | 2025 | Orladeyo |
| Abbvie INC. | $19.99 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.35 | 2021 | |
| Optinose US, INC. | $15.82 | 2024 | |
| Mannkind Corporation | $11.62 | 2020 | |
| Bardy Diagnostics, INC. | $10.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.